DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Intrauterine misoprostol for the prevention of bleeding cesarean]

Author(s): Quiroga Diaz R, Cantu Mata R, Tello Gutierrez HE, Puente Villalobos M, Montemayor Garza R, Martinez Mendoza A

Affiliation(s): Hospital de Ginecologia y Obstetricia de Monterrey.

Publication date & source: 2009-10, Ginecol Obstet Mex., 77(10):469-74.

Publication type: English Abstract; Randomized Controlled Trial

OBJECTIVE: To evaluate efficacy of misoprostol by intrauterine route for the prevention of the obstetrical hemorrhage and to know its effects collaterals. PATIENTS AND METHODS: Clinical and randomized test with 200 patients to those who one took place to them Caesarean. The Group A was applied placebo and the group B misoprostol (group B; 800 microg) intrauterine, after the birth of its newborns. The necessity of additional uterotonics was compared, loss of hemoglobin and hematocrit, and the effects collaterals. RESULTS: In group B it diminished the necessity of additional uterotonics to 50% and the loss of hemoglobin in 39.6%. In the group greater loss of 3 was registered g of hemoglobin in 13 versus 3% of the patients. With respect to the hematocrit, its loss was reduced in 40.6%. The patients in those who the hematocrit in more fell than 10%, registered themselves in 7 versus 1% cases. The effects collaterals were few and not so serious. CONCLUSION: The intrauterine combination of misoprostol and oxitocin diminishes the postcaesarean sanguineous loss and has brings about few effects collaterals.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017